## Update on Pharmacoeconomics in the Irish Healthcare Setting



## Date: 23<sup>rd</sup> & 24th March 2015 Venue: Trinity Centre for Health Sciences

## DAY ONE

Morning Session

| 8.30AM          | Course Registration & Refreshments  |             |
|-----------------|-------------------------------------|-------------|
| 9.15 - 10AM     | Introduction to Pharmacoeconomics   | M. Barry    |
| 10.00 - 10.30AM | HTA: The industry perspective       | C. O'Regan  |
| 10.30 - 11.00AM | HTA: The decision maker perspective | S. Flanagan |
| 11.00 – 11.30AM | HTA: Speaker TBC                    |             |
| 11.30 - 12.00PM | Questions and Answer Session        |             |
| 12.00 - 12.45PM | HTA – Why and how?                  | C. Walsh    |

Afternoon Session2.00 - 2.45PMMeasuring effectivenessA. O'Leary2.45 - 3.30PMTime to Event AnalysisL. McCullagh3.45 - 4.15PMCosting HealthC. Usher4.15 - 4.45PMPreferences in HTAR. Adams

## DAY TWO

|                 | Morning Session   |                                       |
|-----------------|---|---------------------------------------|
| 9.00 - 9.45AM   | Title to be confirmed Pro   | of. John Forbes, UL                   |
| 9.45 - 10.15AM  | Measuring Uncertainty in<br>Economic Evaluation   | S. Schmitz                            |
| 10.45 - 11.30AM | A Multiple Criteria Decision Anal   | ysis Approach to HTA<br>S. O'Meachair |
| 11.30 – 12.15AM | Combining Evidence for Econo<br>Evaluations   | mic S. Schmitz                        |
| 12.15 - 12.45PM | Recent pharmaceutical cost con<br>and effects on state-funded dru<br>Republic of Ireland      |                                       |
|                 | Afternoon Session   |                                       |
| 1.30 - 2.30PM   | Workshops:<br>1. Submitting to the NCPE – what do y<br>2. Decision making – separating facts, |                                       |
| 2.30 - 3.30PM   | Outcomes Research:<br>Registries in Ireland – the way forward                                 | d in outcome                          |

measurement (Hepatitis C and Cystic Fibrosis examples)

Incorporating the patient perspective in HTA

Challenges ahead for all

**Closing Remarks** 

3.45 - 4.15PM

4.15 - 4.45PM

4.45PM

A. O'Leary & A. Jackson

C. Walsh

**R.** Adams